Sotera Health CoSHC -0.42%74 Receivables Turnover is 2.03 as of Mar. 2026. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.33 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 79.9% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sotera Health Co's Revenue for the
three
months ended in Mar. 2026 was $280 Mil. Sotera Health Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was $138 Mil.
Hence, Sotera Health Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.03.
Sotera Health Co (NAS:SHC) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sotera Health Co Receivables Turnover Related Terms
Sotera Health Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs VCYT, RDNT, BLLN: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a Receivables Turnover of 2.03 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sotera Health Co and its competitors. According to the industry distribution chart, Sotera Health Co ranks #41 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 20.1%.
Is Sotera Health Co's Receivables Turnover too high?
Sotera Health Co's current Receivables Turnover is 2.03. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Sotera Health Co's value of 2.03 is 62.3% below this industry median. Based on the distribution chart, Sotera Health Co ranks #41 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Receivables Turnover compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #41 out of 204 companies for Receivables Turnover. This places Sotera Health Co in the top 20% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.38. Sotera Health Co's value of 2.03 is 62.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Receivables Turnover of 2.03 is 62.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Receivables Turnover is 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.33, compared to a current price of $17.86 — trading 9.3% above its estimated fair value. The current Receivables Turnover is 2.03 and 62.3% below the Medical Diagnostics & Research industry median of 5.38. Sotera Health Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Receivables Turnover is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.86 is trading 9.3% above its estimated GF Value™ of $16.33.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
Receivables Turnover: 2.03
GF Value™: $16.33 vs. price of $17.86 (9.3% above fair value)
Industry Position: 62.3% below the Medical Diagnostics & Research median (#41 of 204)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
